Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Pablo Bascuñana, Luisa Möhle, Mirjam Brackhan, et al.
Drugs in R&D (2020) Vol. 20, Iss. 3, pp. 197-207
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series
Arsh Haj Mohamad Ebrahim Ketabforoush, Rojin Chegini, Shirin Barati, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 160, pp. 114378-114378
Open Access | Times Cited: 30
Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases
Yanhong Bu, Hong Wu, Ran Deng, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 41
Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod
Safura Pournajaf, Leila Dargahi, Mohammad Javan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 32
Fingolimod Suppresses NLRP3 Inflammasome Activation and Alleviates Oxidative Stress in Traumatic Brain Injury-Induced Acute Lung Injury
Qi Shi, Tingting Hu, Lixia Xu, et al.
Journal of Inflammation Research (2025) Vol. Volume 18, pp. 2229-2245
Open Access
p21‐Activated Kinase 1 (Pak1) as an Element in Functional and Dysfunctional Interplay Among the Myocardium, Adipose Tissue, and Pancreatic Beta Cells
Paola C. Rosas, R. John Solaro
Comprehensive physiology (2025) Vol. 15, Iss. 2
Open Access
Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system
Ingrid Yao Mattisson, Christina Christoffersen
Atherosclerosis (2021) Vol. 334, pp. 76-84
Open Access | Times Cited: 30
The Role of Sphingolipids and Specialized Pro-Resolving Mediators in Alzheimer’s Disease
Nienke M. de Wit, Kevin Mol, Sabela Rodríguez‐Lorenzo, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 27
Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection
Wolfgang Löscher, Charles L. Howe
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 21
Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease
Pablo Bascuñana, Mirjam Brackhan, Luisa Möhle, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 331-331
Open Access | Times Cited: 10
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Volkmar Leßmann, Georgia-Ioanna Kartalou, Thomas Endres, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 8, pp. 1003-1012
Open Access | Times Cited: 10
Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders
Fatemeh Rahmati‐Dehkordi, Hadi Khanifar, Nazanin Najari, et al.
Neurochemical Research (2024) Vol. 49, Iss. 10, pp. 2668-2681
Closed Access | Times Cited: 3
Intersecting Pathways: The Role of Metabolic Dysregulation, Gastrointestinal Microbiome, and Inflammation in Acute Ischemic Stroke Pathogenesis and Outcomes
Jarosław Nuszkiewicz, Beata Kukulska-Pawluczuk, Katarzyna Piec, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4258-4258
Open Access | Times Cited: 3
Fingolimod effects on the brain are mediated through biochemical modulation of bioenergetics, autophagy, and neuroinflammatory networks
Mehdi Mirzaei, Morteza Abyadeh, A Turner, et al.
PROTEOMICS (2022) Vol. 22, Iss. 19-20
Open Access | Times Cited: 17
Ceramide and Sphingosine-1-Phosphate in Neurodegenerative Disorders and Their Potential Involvement in Therapy
Cristina Tringali, Paola Giussani
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 7806-7806
Open Access | Times Cited: 16
Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
Siyao Li, Koki Sakurai, Masahiro Ohgidani, et al.
Molecular Brain (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 9
Fatty acid elongation by ELOVL6 hampers remyelination by promoting inflammatory foam cell formation during demyelination
Aida V. Garcia Corrales, Sanne G. S. Verberk, Mansour Haidar, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 37
Open Access | Times Cited: 9
Critical Roles of Lysophospholipid Receptors in Activation of Neuroglia and Their Neuroinflammatory Responses
Bhakta Prasad Gaire, Ji-Woong Choi
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 7864-7864
Open Access | Times Cited: 20
CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice
Tina Sepasi, Tahereh Ghadiri, Abbas Ebrahimi‐Kalan, et al.
International Journal of Pharmaceutics (2023) Vol. 636, pp. 122815-122815
Closed Access | Times Cited: 8
A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis
María José Aguilar-Castillo, Pablo Cabezudo‐García, Guillermina García Martín, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6488-6488
Open Access | Times Cited: 2
Exploring the molecular targets of fingolimod and siponimod for treating the impaired cognition of schizophrenia using network pharmacology and molecular docking
Chao Li, Chuanjun Zhuo, Xiaoyan Ma, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Lessons from S1P receptor targeting in multiple sclerosis
Emanuela Colombo, Cinthia Farina
Pharmacology & Therapeutics (2021) Vol. 230, pp. 107971-107971
Closed Access | Times Cited: 18
Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies
María José Aguilar-Castillo, Pablo Cabezudo‐García, Nicolás Lundahl Ciano-Petersen, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 716-716
Open Access | Times Cited: 13
Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson’s Disease
Joanna Motyl, Joanna B. Strosznajder, Agnieszka Wencel, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6277-6277
Open Access | Times Cited: 17
Age-Related Transcriptional Deregulation of Genes Coding Synaptic Proteins in Alzheimer's Disease Murine Model: Potential Neuroprotective Effect of Fingolimod
Henryk Jęśko, Iga Wieczorek, P.L. Wencel, et al.
Frontiers in Molecular Neuroscience (2021) Vol. 14
Open Access | Times Cited: 17
Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis
Celia Camacho-Toledano, Isabel Machín-Díaz, Leticia Calahorra, et al.
Journal of Neuroinflammation (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top